Diamel in the Treatment of Metabolic Syndrome
Sponsored by Catalysis SL
About this trial
Last updated 16 years ago
Study ID
CAT-0918-CU
Status
Completed
Type
Interventional
Phase
Phase 3
Placebo
Yes
Accepting
19 to 70 Years
All Sexes
Trial Timing
Ended 16 years ago
What is this trial about?
The purpose of this study is to assess the efficacy of Diamel administration in the treatment of Metabolic Syndrome. The duration of this double-blind placebo controlled phase 3 clinical trial will be 12 months.
What are the participation requirements?
Inclusion Criteria
* Metabolic syndrome diagnosis according to WHO definition, with or without glucose intolerance.
* Signed informed consent
Exclusion Criteria
* Type 1 diabetes
* Type 2 diabetes treated with oral hypoglycemic drugs and/or insulin
* Other diseases associated with insulin resistance (eg. Acromegalia, endogenous hypercortisolism, etc)
* Neuropathies or hepatic conditions diagnosed biochemically or by clinical exam.
* Mild or severe heart conditions (eg. heart failure, ischemic cardiopathy)
* Sepsis or any other condition that could potentially interfere with treatment
* Any other treatment that could potentially interfere with treatment
* Pregnancy